Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137388

Published: 2020

Journal Articles

JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis

Jean Grisouard, Sai Li, Lucia Kubovcakova, Tata Nageswara Rao, Sara C. Meyer, Pontus Lundberg, Hui Hao-Shen, Vincent Romanet, Masato Murakami, Thomas Radimerski, Stephan Dirnhofer, Radek C. Skoda

Blood (2016) 128 (6): 839–851.

https://doi.org/10.1182/blood-2015-12-689216

Published: 2016

Includes: Supplemental data

Journal Articles

Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BO25341)

Sarit Assouline, MD MSc, Valeria Buccheri, MD PhD, Alain Delmer, MD, Gianluca Gaidano, MD PhD, Michael Brewster, BSc, Olivier Catalani, Sai Li, MD PhD, Christine McIntyre, PhD, Pakeeza Sayyed, PhD, Xavier C Badoux, MBBS

Blood (2014) 124 (21): 1995.

https://doi.org/10.1182/blood.V124.21.1995.1995

Published: 2014

Journal Articles

Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms

Franz X. Schaub, Renate Looser, Sai Li, Hui Hao-Shen, Thomas Lehmann, Andre Tichelli, Radek C. Skoda

Blood (2010) 115 (10): 2003–2007.

https://doi.org/10.1182/blood-2009-09-245381

Published: 2010

Includes: Supplemental data

Journal Articles

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2 -V617F mutations

Sai Li, Robert Kralovics, Gennaro De Libero, Alexandre Theocharides, Heinz Gisslinger, Radek C. Skoda

Blood (2008) 111 (7): 3863–3866.

https://doi.org/10.1182/blood-2007-09-111971

Published: 2008

Includes: Supplemental data

Journal Articles

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

Daniela Pietra, Sai Li, Angela Brisci, Francesco Passamonti, Elisa Rumi, Alexandre Theocharides, Maurizio Ferrari, Heinz Gisslinger, Robert Kralovics, Laura Cremonesi, Radek Skoda, Mario Cazzola

Blood (2008) 111 (3): 1686–1689.

https://doi.org/10.1182/blood-2007-07-101576

Published: 2008

Includes: Supplemental data

Journal Articles

Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis.

Daniela Pietra, Sai Li, Angela Brisci, Francesco Passamonti, Elisa Rumi, Alexandre Theocharides, Heinz Gissingler, Robert Kralovics, Laura Cremonesi, Radek C. Skoda, Mario Cazzola

Blood (2007) 110 (11): 263.

https://doi.org/10.1182/blood.V110.11.263.263

Published: 2007

Journal Articles

Lineage Distribution of JAK2 Exon12 Mutations and JAK2-V617F in Patients with Polycythemia Vera

Sai Li, Robert Kralovics, Gennaro De Libero, Andre Tichelli, Radek C. Skoda

Blood (2007) 110 (11): 1527.

https://doi.org/10.1182/blood.V110.11.1527.1527

Published: 2007

Journal Articles

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders

Robert Kralovics, Soon-Siong Teo, Sai Li, Alexandre Theocharides, Andreas S. Buser, Andre Tichelli, Radek C. Skoda

Blood (2006) 108 (4): 1377–1380.

https://doi.org/10.1182/blood-2005-11-009605

Published: 2006

Includes: Supplemental data

NARROW

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis

Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2 -V617F mutations

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis.

Lineage Distribution of JAK2 Exon12 Mutations and JAK2-V617F in Patients with Polycythemia Vera

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only